These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 4930721)

  • 1. Discussion on control of new drugs.
    Practitioner; 1971 Apr; 206(234):546-50. PubMed ID: 4930721
    [No Abstract]   [Full Text] [Related]  

  • 2. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom.
    Cahal DA
    Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-marketing surveillance.
    Lasagna L
    Triangle; 1980; 19(3-4):107-11. PubMed ID: 7013216
    [No Abstract]   [Full Text] [Related]  

  • 4. Crying wolf on drug safety.
    Br Med J (Clin Res Ed); 1982 Jan; 284(6311):219-20. PubMed ID: 6799107
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: The drug makers.
    Med J Aust; 1974 Oct; 2(16):583-4. PubMed ID: 4437418
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Bull (Edinb); 1981 Nov; 39(6):356-66. PubMed ID: 7035401
    [No Abstract]   [Full Text] [Related]  

  • 7. Side-effects of drugs. Monitoring adverse reactions.
    Heenan A
    Nurs Times; 1989 Sep 27-Oct 3; 85(39):25-9. PubMed ID: 2587304
    [No Abstract]   [Full Text] [Related]  

  • 8. Monitoring of adverse reactions to drugs in the United Kingdom.
    Inman WH
    Proc R Soc Med; 1970 Dec; 63(12):1302-4. PubMed ID: 5490790
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drugs: from research to consumer].
    Krankenpflege (Frankf); 1978 Nov; 32(11):366-8. PubMed ID: 213643
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacovigilance in the framework of recording and control of drugs in the United Kingdom].
    Dunlop D
    Therapie; 1974; 29(6):799-804. PubMed ID: 4462229
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-marketing surveillance of adverse reactions to new medicines.
    Wilson AB
    Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357
    [No Abstract]   [Full Text] [Related]  

  • 12. Communicating adverse drug reactions.
    Lancet; 1978 Jan; 1(8056):133. PubMed ID: 87560
    [No Abstract]   [Full Text] [Related]  

  • 13. [Intensified drug control--with drawbacks?].
    Böttiger LE
    Lakartidningen; 1983 Feb; 80(7):575-81. PubMed ID: 6855371
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitored drug usage in a hospital environment.
    Macgregor AG
    N Z Med J; 1969 Jun; 69(445):356-9. PubMed ID: 5257555
    [No Abstract]   [Full Text] [Related]  

  • 15. Requirements to be fulfilled before instituting clinical trials on new drugs.
    Griffin JP
    Proc R Soc Med; 1974 Jun; 67(7):581-4. PubMed ID: 4605052
    [No Abstract]   [Full Text] [Related]  

  • 16. Control and distribution of medicines in the future.
    Cook AM
    R Soc Health J; 1971; 91(5):222-4. PubMed ID: 5154143
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug trials: non-medical, non-pharmacological, non-psychiatric and non-psychological considerations.
    Amatu HI
    Niger Med J; 1979; 9(7-8):759-65. PubMed ID: 543314
    [No Abstract]   [Full Text] [Related]  

  • 18. Toxicity of new drugs.
    Lowinger P
    Science; 1968 Aug; 161(3842):632. PubMed ID: 5664503
    [No Abstract]   [Full Text] [Related]  

  • 19. Play safe.
    Trans St Johns Hosp Dermatol Soc; 1972; 58(2):283-4. PubMed ID: 4665987
    [No Abstract]   [Full Text] [Related]  

  • 20. Control of new drugs in the United Kingdom.
    Cuthbert MF
    Agents Actions; 1978 Jun; 8(4):410-2. PubMed ID: 685777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.